Palvella TherapeuticsNASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations
Speaking at the Canaccord Conference, Chief Executive Officer Wes Kaupinen said the company’s strategy is centered on delivering first approved therapies in underserved rare-disease settings. He said there are approximately 600 rare skin diseases, with fewer than 2% having approved therapies
Get Palvella Therapeutics alerts:
Lead Program Moves Toward NDA Completion
QTORIN rapamycin is Palvella’s 3.9% anhydrous topical formulation of the mTOR inhibitor rapamycin. The company is developing it initially for microcystic lymphatic malformations, or mLM, a rare genetic and lifelong condition involving malformed lymphatic vessels that protrude through the skin
Kaupinen said the condition can cause lymphatic-fluid discharge, compromised skin barriers, infections including acute cellulitis, bleeding and hospitalizations. He described the disease as progressive if left untreated and said it has no approved therapies. Palvella estimates there are more than 30,000 U.S. patients with mLM
In the company’s 51-patient Phase III study, 95% of patients improved on the Microcystic Lymphatic Malformation Investigator Global Assessment He said 86% of patients were rated “much improved” or “very much improved,” and that the study met its primary endpoint, key secondary endpoint and all prespecified secondary endpoints
Palvella has held a pre-NDA meeting with the FDA and begun a rolling NDA submission. Kaupinen said the company is in the final quality-control stages, is not awaiting further data, and aims to complete the submission before year-end. He said the timeline puts the company on track for a first-half 2027 submission. QTORIN rapamycin has received Breakthrough Therapy, Fast Track and Orphan Drug designations in mLM
Commercial Preparation and Pricing Expectations
The company is preparing to commercialize QTORIN rapamycin in the United States itself if approved. Kaupinen said Palvella has identified roughly 400 U.S. centers managing an estimated 15,000 mLM patients through a claims analysis and is using medical-affairs outreach and its BEYOND mLM disease-awareness campaign to build relationships with treatment centers
Palvella has recruited commercial leadership, including Chief Commercial Officer Ashley Kline, who previously led the U.S. launch of Oxervate at Dompé; Jen McDonough, who led market access and patient services at Krystal Biotech; and Senior Vice President of Sales Kent Taylor, previously at Arcutis
Ad TradeSmith
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investment of 17 million dollars. He is known for predicting the 2020 market crash with striking accuracy.nnToday he is hosting a free live demo of his newest AI-driven trading approach, showing how he analyzes market data without guesswork or speculation.
Register now to watch the free AI trading demo live
